Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez des patients atteints de MASH et DT2
15 nov. 2024 16h00 HE
|
INVENTIVA
Les résultats seront présentés lundi 18 novembre par poster lors de la session « late-breaker » du congrès de l’AASLD The Liver Meeting® à San Diego.L'étude LEGEND a atteint son critère principal...
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
15 nov. 2024 16h00 HE
|
INVENTIVA
Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its...
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 16h05 HE
|
Fractyl Health, Inc.
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
24 sept. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
Fractyl Health to Participate in Upcoming September Investor Conferences
03 sept. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Participate in Upcoming September Investor Conferences
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 août 2024 16h05 HE
|
Fractyl Health, Inc.
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
13 mai 2024 16h00 HE
|
Fractyl Health, Inc.
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
01 avr. 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
05 janv. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist
Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure
14 déc. 2023 05h45 HE
|
Fractyl Health, Inc.
Fractyl Health Announces New Pooled Analysis From Revita Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance without Gain